Evaluation of effects of chronic dose exposure to cardioselective and non-cardioselective beta blockers on measures of cardiopulmonary function in moderate to severe COPD. - Beta Blocker therapy in moderate to severe COPD. ANDA2

Tayside Clinical Trials Unit, University of Dundee0 sites45 target enrollmentJuly 27, 2012

Overview

No summary available.

Registry

who.int

Start Date

July 27, 2012

End Date

July 21, 2016

Last Updated

6 years ago

Study Type

Interventional clinical trial of medicinal product

Sponsor

Tayside Clinical Trials Unit, University of Dundee

•Male and female volunteers aged 40\-80 years with stable moderate to severe COPD (GOLD stage 2\&3\).
•FEV1 30\-80% predicted and FEV1/FVC ratio \<70%.
•Stable defined as no exacerbation in previous 3 months.
•Smoking history \=10 pack\-years.
•Oxygen saturations\= 92% on room air at rest.
•ECG demonstrating sinus rhythm.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range 9

•Uncontrolled symptoms of COPD.
•A COPD exacerbation requiring systemic steroid therapy within 3 months prior to study commencement.
•Use of domiciliary oxygen.
•History of other primary obstructive lung disease including asthma or bronchiectasis.
•History of unstable angina, uncontrolled hypertension or heart failure NYHA class 3\-4\.
•Overt clinical signs of right heart failure.
•Average resting systolic BP\<110mmHg or average resting HR\<60bpm.
•Pregnancy or lactation.
•Known or suspected sensitivity to / intolerance of IMP.
•Inability to comply with compulsory aspects of protocol.